Aytu biopharma announces paydown and refinancing of term loan on more favorable terms

Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the company $1.3 million over the life of the term loan term loan maturity extended to june 12, 2028 extension of revolving credit facility increases potential borrowing capacity denver, co / accesswire / june 18, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the company. in addition, the company received $3.5 million of additional capital through the exercise of warrants from its june 2023 equity financing, a portion of which was used to pay down the term loan indebtedness.
AYTU Ratings Summary
AYTU Quant Ranking